Literature DB >> 18430853

Transcatheter arterial chemoembolization in patients with hepatocellular carcinoma on the waiting list for orthotopic liver transplantation.

Esther Alba1, Carlos Valls, Juan Dominguez, Laura Martinez, Elena Escalante, Laura Lladó, Teresa Serrano.   

Abstract

OBJECTIVE: The objective of this study was to perform a retrospective analysis of patients with hepatocellular carcinoma (HCC) who underwent transcatheter arterial chemoembolization (TACE) before undergoing liver transplantation at our institution. SUBJECTS AND METHODS: From January 2000 to August 2005, 56 patients with HCC underwent TACE before orthotopic liver transplantation (OLT). Radiologic findings before and after TACE were assessed and correlated with histologic findings after OLT. The area of induced necrosis was pathologically evaluated in each HCC nodule.
RESULTS: One hundred thirty-one HCC nodules were detected at histologic study. One hundred seventeen HCC nodules (91.4%) were hyperenhancing in the arterial phase on the preoperative imaging studies. The percentage of tumor necrosis was greater than 90% in 48 nodules (38%), between 50% and 90% in 19 nodules (15%), and less than 50% in 61 nodules (48%); tumor necrosis data were not recorded for the remaining three nodules. The size of the preoperatively detected lesions ranged from 0.2 to 9 cm (mean, 2.58 cm). The mean percentage of tumor necrosis was 67.8% in this group, but it rose to 79.2% in the hypervascular lesions. The size of the nodules that were not detected preoperatively ranged from 0.1 to 1.9 cm (mean, 0.68 cm), and the mean percentage of tumor necrosis was only 1.57%.
CONCLUSION: TACE is a safe treatment in well-selected patients. Its antitumoral effect is high in hypervascular lesions (mean necrosis, 79.2%). It provides good local control in preoperatively diagnosed HCC (mean necrosis, 67.8%), but its impact is limited in lesions not detected preoperatively (mean necrosis, 1.57%).

Entities:  

Mesh:

Year:  2008        PMID: 18430853     DOI: 10.2214/AJR.07.2972

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  17 in total

Review 1.  Loco-regional therapies for patients with hepatocellular carcinoma awaiting liver transplantation: Selecting an optimal therapy.

Authors:  Thomas J Byrne; Jorge Rakela
Journal:  World J Transplant       Date:  2016-06-24

Review 2.  The management of patients awaiting liver transplantation.

Authors:  Ka-Kit Li; James Neuberger
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-10-06       Impact factor: 46.802

Review 3.  Hepatocellular carcinoma: A global view.

Authors:  Ju Dong Yang; Lewis R Roberts
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-07-13       Impact factor: 46.802

Review 4.  When to consider liver transplantation in hepatocellular carcinoma patients?

Authors:  Ka Wing Ma; Tan To Cheung
Journal:  Hepat Oncol       Date:  2017-07-06

Review 5.  Epidemiology and management of hepatocellular carcinoma.

Authors:  Ju Dong Yang; Lewis R Roberts
Journal:  Infect Dis Clin North Am       Date:  2010-12       Impact factor: 5.982

Review 6.  Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience.

Authors:  Matthew M Yeh; Raymond S Yeung; Smith Apisarnthanarax; Renuka Bhattacharya; Carlos Cuevas; William P Harris; Tony Lim Kiat Hon; Siddharth A Padia; James O Park; Kevin M Riggle; Sayed S Daoud
Journal:  World J Hepatol       Date:  2015-06-18

Review 7.  Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.

Authors:  Maurizio Pompili; Giampiero Francica; Francesca Romana Ponziani; Roberto Iezzi; Alfonso Wolfango Avolio
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 8.  Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future.

Authors:  Hwi Young Kim; Joong-Won Park
Journal:  Liver Cancer       Date:  2014-03       Impact factor: 11.740

9.  Stereotactic Body Radiation Therapy: A New Strategy for Loco-Regional Treatment for Hepatocellular Carcinoma While Awaiting Liver Transplantation.

Authors:  Tadahiro Uemura; Alexander Kirichenko; Mark Bunker; Molly Vincent; Lorenzo Machado; Ngoc Thai
Journal:  World J Surg       Date:  2019-03       Impact factor: 3.352

10.  The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.

Authors:  Xu-Dong Qu; Cheng-Shi Chen; Jian-Hua Wang; Zhi-ping Yan; Jie-min Chen; Gao-quan Gong; Qin-xin Liu; Jian-jun Luo; Lin-xiao Liu; Rong Liu; Sheng Qian
Journal:  BMC Cancer       Date:  2012-06-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.